Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients-Reference-Cited by-同舟云学术

Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients

Published:2019-03-25 Issue:6 Volume:58 Page:891-896
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Boons Christel C. L. M.¹²,Tromp Vashti N. M. F.¹²,Neppelenbroek Nienke J. M.¹,Timmers Lonneke¹²,van Schoor Natasja M.³,Swart Eleonora L.¹,Hendrikse N. Harry¹⁴,Janssen Jeroen J. W. M.⁵,Hugtenburg Jacqueline G.¹²

Affiliation:

1. Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands;

2. Amsterdam Public Health research institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands;

3. Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, Amsterdam, Netherlands;

4. Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands;

5. Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands

Funder

Novartis

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2019.1585944

Reference40 articles.

1. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

3. Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

4. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

5. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between patient satisfaction with information and adherence to oral anticancer agents;Journal of Oncology Pharmacy Practice;2022-02-07

2. Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib;European Journal of Clinical Pharmacology;2020-06-02